All In MedTech

Device Trial Radar · NCT03592017

Performance of Long-wavelength Autofluorescence Imaging

Performance of Optimized Long-wavelength Fundus Autofluorescence Imaging in Patients With Retinal Diseases

Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

262

Actual

Start

Oct 1, 2018

Primary completion

Apr 9, 2024

Study completion Apr 9, 2024

Sponsor

Lead sponsor
Oxford University Hospitals NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 19, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Fundus autofluorescence imaging has become an important diagnostic tool in ophthalmology, guiding diagnosis and assessment of progression of retinal diseases. This study investigates the performance of optimized long-wavelength autofluorescence imaging. To achieve this goal, the investigators will determine an optimal long wavelength excitation light and investigate the autofluorescence signal intensity in normals and patients with different retinal diseases. The diagnostic performance of the long-wavelength autofluorescence will be evaluated by assessing sensitivity and specificity for diagnosing a variety of degenerative retinal diseases and by comparing it to conventional autofluorescence.

Conditions

  • Retinal Disease
  • Retinal Degeneration
  • Retinal Dystrophies

Interventions

  • Long-wavelength autofluorescence imagingDevice

    Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Performance of long-wavelength autofluorescence imagingTime frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oxford Eye Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.